Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $55

Benzinga Newsdesk www.benzinga.com Positive 72.9%

Neg 0% Neu 0% Pos 72.9%

Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $50 to $55.